US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Vivos Inc.

0.0840

-0.0010-1.18%

Volume:519.70K

Turnover:43.07K

Market Cap:38.19M

PE:-12.18

High:0.0887

Open:0.0887

Low:0.0801

Close:0.0850

52wk High:0.1657

52wk Low:0.0425

Shares:454.66M

Float Shares:434.00M

Volume Ratio:0.45

T/O Rate:0.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0069

EPS(LYR):-0.0043

ROE:-178.25%

ROA:-96.45%

PB:-5.33

PE(LYR):-19.56

Loading ...

Overview Company News Filings

BRIEF-Vivos Inc. Announces Progress Toward FDA Investigational Device Exemption (Ide) Submission

Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (Ide) Submission for Radiogel® Precision Radionuclide Therapy™

THOMSON REUTERS

Vivos Inc. Advances RadioGel Clinical Trial in India for Solid Tumor Therapy

Vivos Inc Updates Human Therapy Progress in India

THOMSON REUTERS

Vivos Inc. Secures U.S. Patent for Innovative Radiotherapy Gel Technology

Vivos Inc. CEO and President Michael K. Korenko Acquires Common Shares

Vivos Inc. CEO and President Michael K. Korenko Acquires Common Shares

Vivos Inc. Issues Shareholder Update Letter

THOMSON REUTERS

BRIEF-Vivos Inc. Strengthens Strategic Collaboration With Exubrion Therapeutics

BRIEF-Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., To Support Ide Submission For Radiogel®

Vivos Inc. Retains Top FDA Regulatory Expert DR. John J. Smith, M.d., J.d., to Support Ide Submission for Radiogel®

THOMSON REUTERS

BRIEF-Vivos Board Authorizes To Establish A Corporate Entity In India

Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India

THOMSON REUTERS

Vivos Inc. Issues Correction to 8-K Filing, Clarifies Details on Executive Appointment

Vivos Inc. Announces Key Leadership Appointments: Brad Allan Weeks Named President, David J. Swanberg Appointed Chief Operating Officer

Vivos Inc. CEO and President Michael Korenko Reports Acquisition of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RDGL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RDGL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RDGL\",,,,,undefined,":{"symbol":"RDGL","market":"US","secType":"STK","nameCN":"Vivos Inc.","latestPrice":0.084,"timestamp":1771621200000,"preClose":0.085,"halted":0,"volume":519702,"delay":15,"changeRate":-0.011764705882352951,"floatShares":434000000,"shares":454664957,"eps":-0.006898,"marketStatus":"Market Closed","change":-0.001,"latestTime":"02-20 16:00:00 EST Delay","open":0.0887,"high":0.0887,"low":0.0801,"amount":43067.846699999995,"amplitude":0.101176,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.006898,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.085,"volumeRatio":0.44800413502008196},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RDGL\",,,,,undefined,":{"symbol":"RDGL","floatShares":434000000,"roa":"-96.45%","roe":"-178.25%","lyrEps":-0.004295,"volumeRatio":0.44800413502008196,"shares":454664957,"dividePrice":0,"high":0.0887,"amplitude":0.101176,"preClose":0.085,"low":0.0801,"week52Low":0.0425,"pbRate":"-5.33","psRate":"785.49","week52High":0.1657,"institutionHeld":0,"latestPrice":0.084,"eps":-0.006898,"divideRate":0,"volume":519702,"delay":15,"ttmEps":-0.006898,"open":0.0887,"prevYearClose":0.0689,"prevWeekClose":0.0779,"prevMonthClose":0.068,"prevQuarterClose":0.0689,"fiveDayClose":0.075,"twentyDayClose":0.0668,"sixtyDayClose":0.072},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RDGL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-13","symbol":"RDGL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-08-13","symbol":"RDGL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-09","symbol":"RDGL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-03-18","symbol":"RDGL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1710734400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2023-11-06","symbol":"RDGL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1699246800000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RDGL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RDGL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RDGL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2610230866","title":"BRIEF-Vivos Inc. Announces Progress Toward FDA Investigational Device Exemption (Ide) Submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2610230866","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610230866?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:42","pubTimestamp":1770730954,"startTime":"0","endTime":"0","summary":"BRIEF-Vivos Inc. Announces Progress Toward FDA Investigational Device Exemption (Ide) Submission Feb 10 (Reuters) - Vivos Inc RDGL.PK:VIVOS INC. ANNOUNCES SIGNIFICANT PROGRESS TOWARD FDA INVESTIGATION","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUABD7PZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","RDGL"],"gpt_icon":0},{"id":"2610949623","title":"Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (Ide) Submission for Radiogel® Precision Radionuclide Therapy™","url":"https://stock-news.laohu8.com/highlight/detail?id=2610949623","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610949623?lang=en_us&edition=fundamental","pubTime":"2026-02-10 21:30","pubTimestamp":1770730204,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nTUABD7PZV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RDGL","BK4082"],"gpt_icon":0},{"id":"2608687126","title":"Vivos Inc. Advances RadioGel Clinical Trial in India for Solid Tumor Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2608687126","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608687126?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:30","pubTimestamp":1770125448,"startTime":"0","endTime":"0","summary":"Vivos Inc. has provided an update on its ongoing human therapy demonstrations in India using RadioGel Precision Radionuclide Therapy. The study, initiated in December 2024, involves treatment of patients to demonstrate safety and measure efficacy. According to the company, several patients have completed their one-year follow-up examinations without reports of serious adverse events or damage to adjacent organs. Preliminary observations indicate instances of tumor size reduction with no recurrence in specific cases during the follow-up period. The company anticipates regulatory clearance from the Drug Controller General of India  later this quarter to proceed with a larger-scale clinical trial. Comprehensive results from these demonstrations have not yet been presented but are planned for submission and peer-review as part of the ongoing regulatory process.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL6yQgnJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","BK4082","LU2210150020.SGD","LU2210149790.SGD","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","RDGL","IE00BKPKM429.USD","BK4585","BK4112"],"gpt_icon":0},{"id":"2608871478","title":"Vivos Inc Updates Human Therapy Progress in India","url":"https://stock-news.laohu8.com/highlight/detail?id=2608871478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608871478?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:30","pubTimestamp":1770125401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA8H71B8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","RDGL"],"gpt_icon":0},{"id":"2606110587","title":"Vivos Inc. Secures U.S. Patent for Innovative Radiotherapy Gel Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2606110587","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606110587?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:30","pubTimestamp":1769607022,"startTime":"0","endTime":"0","summary":"Vivos Inc. has announced the issuance of U.S. Patent No. 12,521,452 B2, titled \"Radiotherapy Gel and Method of Preparing the Same,\" granted by the United States Patent and Trademark Office on January 13, 2026. The patent protects critical advancements in the company’s proprietary Precision Radionuclide Therapy platform, which underpins its RadioGel and IsoPet products. Additionally, Vivos has filed a new patent application covering the use of its hydrogel technology as a carrier for a range of therapeutic agents, including anti-cancer and gene therapy agents, enabling timed release once formed into a gel after injection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDLb7v4qg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014005.SGD","IE00BKPKM429.USD","BK4585","LU0314104364.USD","RDGL","SG9999014021.USD","BK4082","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ"],"gpt_icon":0},{"id":"2600936061","title":"Vivos Inc. CEO and President Michael K. Korenko Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2600936061","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600936061?lang=en_us&edition=fundamental","pubTime":"2026-01-03 00:07","pubTimestamp":1767370022,"startTime":"0","endTime":"0","summary":"Michael K. Korenko, CEO and President of Vivos Inc., reported the acquisition of common shares of Vivos Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260102:nNDL2TsTVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivos Inc. CEO and President Michael K. Korenko Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RDGL","BK4082"],"gpt_icon":0},{"id":"2585901161","title":"Vivos Inc. CEO and President Michael K. Korenko Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2585901161","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585901161?lang=en_us&edition=fundamental","pubTime":"2025-11-21 08:35","pubTimestamp":1763685309,"startTime":"0","endTime":"0","summary":"Michael K. Korenko, CEO and President of Vivos Inc., reported the acquisition of common shares of Vivos Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 20, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL6QmZbb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivos Inc. CEO and President Michael K. Korenko Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RDGL","BK4082"],"gpt_icon":0},{"id":"2581095705","title":"Vivos Inc. Issues Shareholder Update Letter","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095705?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:30","pubTimestamp":1762435803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nTUALX3GK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RDGL","BK4082"],"gpt_icon":0},{"id":"2579907399","title":"BRIEF-Vivos Inc. Strengthens Strategic Collaboration With Exubrion Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2579907399","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579907399?lang=en_us&edition=fundamental","pubTime":"2025-10-29 22:22","pubTimestamp":1761747722,"startTime":"0","endTime":"0","summary":"BRIEF-Vivos Inc. Strengthens Strategic Collaboration With Exubrion TherapeuticsVivos Inc RDGL.PK:VIVOS INC. STRENGTHENS STRATEGIC COLLABORATION WITH EXUBRION THERAPEUTICSSource text: ID:nGNX7LhGkxFurther company coverage: RDGL.PK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUABPVMBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","RDGL"],"gpt_icon":0},{"id":"2578808642","title":"BRIEF-Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., To Support Ide Submission For Radiogel®","url":"https://stock-news.laohu8.com/highlight/detail?id=2578808642","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578808642?lang=en_us&edition=fundamental","pubTime":"2025-10-27 21:40","pubTimestamp":1761572456,"startTime":"0","endTime":"0","summary":"BRIEF-Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., To Support Ide Submission For RadiogelOct 27 (Reuters) - Vivos Inc RDGL.PK:VIVOS INC. RETAINS TOP FDA REGULATORY EXPER","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUA2KNCYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","RDGL"],"gpt_icon":0},{"id":"2578461596","title":"Vivos Inc. Retains Top FDA Regulatory Expert DR. John J. Smith, M.d., J.d., to Support Ide Submission for Radiogel®","url":"https://stock-news.laohu8.com/highlight/detail?id=2578461596","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578461596?lang=en_us&edition=fundamental","pubTime":"2025-10-27 20:30","pubTimestamp":1761568202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUA2KNCYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RDGL","BK4082"],"gpt_icon":0},{"id":"2571352354","title":"BRIEF-Vivos Board Authorizes To Establish A Corporate Entity In India","url":"https://stock-news.laohu8.com/highlight/detail?id=2571352354","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571352354?lang=en_us&edition=fundamental","pubTime":"2025-09-30 02:27","pubTimestamp":1759170448,"startTime":"0","endTime":"0","summary":"BRIEF-Vivos Board Authorizes To Establish A Corporate Entity In IndiaSept 29 (Reuters) - Vivos Inc RDGL.PK:VIVOS INC BOARD AUTHORIZES VIVOS INC TO ESTABLISH A CORPORATE ENTITY IN INDIAVIVOS INC - FILE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RDGL","BK4082"],"gpt_icon":0},{"id":"2571794359","title":"Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India","url":"https://stock-news.laohu8.com/highlight/detail?id=2571794359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571794359?lang=en_us&edition=fundamental","pubTime":"2025-09-30 01:46","pubTimestamp":1759167983,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nFWN3VG0AO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RDGL","BK4082"],"gpt_icon":0},{"id":"2569777264","title":"Vivos Inc. Issues Correction to 8-K Filing, Clarifies Details on Executive Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2569777264","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569777264?lang=en_us&edition=fundamental","pubTime":"2025-09-24 18:02","pubTimestamp":1758708179,"startTime":"0","endTime":"0","summary":"Vivos Inc. has issued an amendment to its previously filed Form 8-K, correcting typographical errors in the section regarding the appointment of David J. Swanberg. The amendment, filed on September 23, 2025, clarifies details related to executive appointments and related agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250924:nNDL6wvhyv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","RDGL"],"gpt_icon":0},{"id":"2569719003","title":"Vivos Inc. Announces Key Leadership Appointments: Brad Allan Weeks Named President, David J. Swanberg Appointed Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2569719003","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569719003?lang=en_us&edition=fundamental","pubTime":"2025-09-23 23:16","pubTimestamp":1758640598,"startTime":"0","endTime":"0","summary":"Vivos Inc. Announces Key Leadership Appointments: Brad Allan Weeks Named President, David J. Swanberg Appointed Chief Operating Officer. Vivos Inc. has announced key management changes with the appointment of Brad Allan Weeks as the new President, effective September 15, 2025. Mr. Weeks previously held the position of Business Development Manager for the company's IsoPet and RadioGel divisions. Additionally, David J. Swanberg has been appointed as the Chief Operating Officer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Septembe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL7w43vd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RDGL","BK4082"],"gpt_icon":0},{"id":"2559096995","title":"Vivos Inc. CEO and President Michael Korenko Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2559096995","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559096995?lang=en_us&edition=fundamental","pubTime":"2025-08-15 02:47","pubTimestamp":1755197243,"startTime":"0","endTime":"0","summary":"Michael Korenko, CEO and President of Vivos Inc., reported an acquisition of common shares of Vivos Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 14, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDL7zNBC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RDGL","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}